Pallas Capital Advisors LLC Blueprint Medicines Corp Transaction History
Pallas Capital Advisors LLC
- $2.31 Billion
- Q1 2024
A detailed history of Pallas Capital Advisors LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 5,229 shares of BPMC stock, worth $584,079. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,229
Previous 5,197
0.62%
Holding current value
$584,079
Previous $479,000
3.55%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding BPMC
# of Institutions
313Shares Held
60.6MCall Options Held
634KPut Options Held
691K-
Black Rock Inc. New York, NY6.45MShares$720 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$705 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.25MShares$698 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$466 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.5MShares$279 Million6.2% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.67B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...